Source-grounded facts extracted from Shuttle Pharmaceuticals Holdings, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Shuttle Pharmaceuticals Holdings, Inc.: Filed a certificate of amendment to effect a 1-for-10 reverse stock split of common stock (effective 2026-06-11).
“on June 10, 2026, the Company filed a certificate of amendment to amend the certificate of incorporation of the Company (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, with an effective date of June 11, 2026 (the “Effective Date”).”
Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Authorization of the Board of Directors to Effect one or more Reverse Stock Split(s) of the Common Stock at a Ratio Between 1-for-2 and 1-for-150 at the 2026-05-21 meeting.
“Proposal No. 4: Authorization of the Board of Directors to Effect one or more Reverse Stock Split(s) of the Common Stock at a Ratio Between 1-for-2 and 1-for-150 For Against Abstentions 3,055,436 119,431 200,205”
Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-21 meeting.
“Proposal No. 3: Advisory Vote on Executive Compensation (“Say on Pay”) For Against Abstentions Broker Non-Votes 2,650,932 39,906 101,870 582,364”
Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Ratification of Appointment of Forvis Mazars, LLP as the Company’s Independent Registered Public Accounting Firm at the 2026-05-21 meeting.
“Proposal No. 2: Ratification of Appointment of Forvis Mazars, LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026. For Against Abstentions 3,191,174 12,417 171,481”
Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Election of Directors at the 2026-05-21 meeting.
“Proposal No. 1: Election of Directors Nominee Name For Withheld Broker Non-Votes Christopher Cooper 2,621,457 171,251 582,364 Adam Chambers 2,616,680 176,028 582,364 George Scorsis 2,664,628 128,080 582,364 Angel Liriano 2,664,666 128,042 582,364 A plurality of the votes cast at the Meeting was required to approve the election of each of the nominees listed above as directors to serve until the 2027 annual meeting of the Company’s stockholders and until each of their respective successors are elected and qualified or until each of their earlier resignation or removal (“Proposal No. 1”). Accordingly, Proposal No. 1 was approved”
Shuttle Pharmaceuticals Holdings, Inc. completed an acquisition involving United Dogecoin Inc. (closed 2026-05-06).
“On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).”
Shuttle Pharmaceuticals Holdings, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Securities Purchase Agreement for issuance of Series B-2 convertible preferred stock and common stoc (effective 2026-04-30).
“on April 30, 2026, the Acquiror entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with certain accredited investors party thereto (each, a “ Purchaser ” and collectively, the “ Purchasers ”), pursuant to which the Acquiror agreed to issue (i) 1,910 newly designated Series B-2 convertible preferred stock, par value $0.00001 (the “ Series B-2 Preferred Stock ”) and (ii) common stock purchase warrants (the “ Common Warrants ” and together with the Series B-2 Preferred Stock, the “ PIPE Securities ”) to purchase up to 100% of the number of shares of Common Stock underlying the Series B-2 Convertible Preferred Stock as of the Closing Date, exercisable for a period of three (3) years at an exercise price of $1.03 per share (the “ PIPE Financing ”).”
Shuttle Pharmaceuticals Holdings, Inc. entered into Agreement and Plan of Merger with United Dogecoin Inc. valued at Agreement and Plan of Merger entered into on April 30, 2026 by and among Acquiror, Merger Sub and th (effective 2026-04-30).
“On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).”
Oleh Nabyt resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..
“On May 3, 2026 (the “ Termination Date ”), independent director Oleh Nabyt resigned from the Board of Directors of Shuttle, effective as of the Termination Date.”
Ryan Trasolini was appointed as Co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..
“the Board of Directors of Shuttle approved the appointment of Ryan Trasolini, Chief Executive Officer of the Company, as Co-Chief Executive Officer of the Acquiror, effective at the Effective Time.”
Shuttle Pharmaceuticals Holdings, Inc. entered into Agreement and Plan of Merger with United Dogecoin Inc. valued at Merger consideration consisting of Series B-1 convertible preferred stock and up to 118,038,551 pre- (effective 2026-04-30).
“On April 30, 2026, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).”
Shuttle Pharmaceuticals Holdings, Inc. entered into Placement Agency Agreement with E.F. Hutton & Co. valued at Placement agency agreement on a reasonable best-efforts basis, with cash fee of 4.0% of gross procee (effective 2026-03-05).
“On March 5, 2026, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with E.F. Hutton & Co., as placement agent (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offering.”
Shuttle Pharmaceuticals Holdings, Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at The Company agreed to issue and sell 2,238,800 shares of common stock and pre-funded warrants to pur (effective 2026-03-05).
“In connection with the Offering, the Company entered into a Securities Purchase Agreement, dated March 5, 2026 (the “Purchase Agreement”), by and among the Company and the purchasers named therein, pursuant to which the Company agreed to issue and sell the shares of Common Stock and Pre-Funded Warrants.”
Shuttle Pharmaceuticals Holdings, Inc. issued 320,496 shares of common stock to 1563868 B.C. Ltd. for $1.76 per share.
“The aggregate number of shares of Company Common Stock issued to Seller on the effective date was 320,496 shares, representing 19.99% of the issued and outstanding shares of Company Common Stock as of the closing date of the Agreement, at a value of $1.76 per share (which value was calculated in accordance with the terms of the Agreement).”
Shuttle Pharmaceuticals Holdings, Inc. amended First Amendment to Asset Purchase Agreement with 1563868 B.C. Ltd., 1542770 BC Ltd., ZhiTian (Andy) Zhang valued at 320,496 shares of Company Common Stock at $1.76 per share (effective 2025-12-23).
“On December 23, 2025 (the “ Effective Date ”), Shuttle Pharmaceuticals Holdings, Inc. (the “ Company ”) entered into a First Amendment (the “ Amendment ”) to Asset Purchase Agreement (the “ Agreement ”) with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary (“ Purchaser ”), 1542770 BC Ltd., a Canadian limited corporation (“ Seller ”), and ZhiTian (Andy) Zhang, an individual residing in Vancouver, Canada (“ Seller Guarantor ”), dated as of November 20, 2025.”
Shuttle Pharmaceuticals Holdings, Inc. entered into Asset Purchase Agreement with 1542770 BC Ltd. and Zhitian (Andy) Zhang valued at a one-time cash contribution of $3,000,000, paid on the Closing Date; (ii) a first installment contr (effective 2025-11-20).
“On November 20, 2025 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “ Agreement ”) with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary (“ Purchaser ”), 1542770 BC Ltd., a Canadian limited corporation (“ Seller ”) and Zhitian (Andy) Zhang, an individual residing in Vancouver, Canada (“ Seller Guarantor ”). Pursuant to the terms and conditions of the Agreement, the Seller sold the Purchaser all of its rights, title and interest in and to substantially all of the assets (collectively, the “ Transferred Assets “) and liabilities (the “ Transferred Liabilities ”) of the Seller. The closing of the transactions contemplated under the Agreement were consummated on the Closing Date. The aggregate consideration payable by or on behalf of the Purchaser for the sale, transfer, and delivery of the Transferred Assets and Transferred Liabilities consists of: (a) a one-time cash c”
Shuttle Pharmaceuticals Holdings, Inc. completed an acquisition involving 1542770 BC Ltd. for aggregate consideration payable ... consists of: (a) a one-time cash contribution of $3,000,000, paid on the Closing Date; (ii) a first installment contribution (closed 2025-11-20).
“by or on behalf of the Purchaser for the sale, transfer, and delivery of the Transferred Assets and Transferred Liabilities consists of: (a) a one-time cash contribution of $3,000,000, paid on the Closing Date; (ii) a first installment contribution equal to $3,000,000, payable on the 6 month anniversary of the Closing Date; and (iii) a second installment”
Shuttle Pharmaceuticals Holdings, Inc. entered into release and settlement agreement between Company and Theradex Systems, Inc. with Theradex Systems, Inc. valued at partial payment of $300,000; release of Outstanding Liabilities of approximately $557,000; Company e (effective 2025-11-20).
“Pursuant to the notice of termination, on November 20, 2025, the Company and Theradex entered into a release and settlement agreement (the “Settlement Agreement”), pursuant to which the Company will pay a partial payment of $300,000 to Theradex as full and final payment of any and all claims relating to the debt or obligation previously owed by the Company to Theradex, totalling approximately $557,000 (the “Outstanding Liabilities”) and in consideration of such payment, each party will release, acquit and discharge each other from all claims arising from the Outstanding Liabilities and Theradex will properly wind down the Clinical Trials (as defined below) in a manner compliant with the Food and Drug Administration.”
Shuttle Pharmaceuticals Holdings, Inc. terminated master agreement between Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc. with Theradex Systems, Inc. valued at Outstanding Liabilities of approximately $557,000; partial payment of $300,000; remaining research s (effective 2025-10-15).
“As previously disclosed by the Company in its Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 21, 2025, on October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) received a letter from Theradex Systems, Inc. (“Theradex”), providing written notice of termination of the master agreement, dated November 1, 2018 (the “Master Agreement”), between Shuttle Pharmaceuticals, Inc. (the Company’s wholly-owned subsidiary) and Theradex, and all work orders thereunder.”
Shuttle Pharmaceuticals Holdings, Inc. announced a restructuring affecting clinical trials of Ropidoxuridine.
“On November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the “Clinical Trials”), as provided for under the Master Agreement.”
Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) reported stockholders’ equity of $1,394,161 in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, and, as a result, was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires”
Shuttle Pharmaceuticals Holdings, Inc. issued up to 625,156 shares of common stock of warrant to the Purchaser for aggregate gross proceeds of approximately $2.5 million.
“to purchase up to 625,156 shares of common stock of the Company, par value $0.00001 per share (the “Common Stock”) for aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees to WestPark Capital, Inc. (the “Placement Agent”) and offering expenses payable by the Company. The Offering closed on November 4, 2025.”
Michael P. Vander Hoek resigned as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..
“On May 9, 2025, Michael P. Vander Hoek submitted his resignation from the position of Vice President, Regulatory, of the Company, effective June 10, 2025.”
Dr. Anatoly Dritschilo resigned as Chief Scientific Offer and director at Shuttle Pharmaceuticals Holdings, Inc..
“On May 9, 2025, Dr. Anatoly Dritschilo, resigned as Chief Scientific Offer and director of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), effective immediately.”
Anatoly Dritschilo was appointed as Chief Scientific Officer at Shuttle Pharmaceuticals Holdings, Inc..
“Anatoly Dritschilo, M.D., to the position of Chief Scientific Officer. Dr. Dritschilo will also continue to hold the position of Chairman of the Board of Directors.”
Christopher Cooper was appointed as interim Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..
“Effective March 30, 2025, the Company’s Board of Directors approved the appointment of Christopher Cooper to the position of interim Chief Executive Officer”
Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).
“September 10, 2024, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was no longer in compliance with Nasdaq Rule 5550(b)(1), the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq (the “Minimum Equity Requirement”). In response to the Notice, the Company submitted its plan of regain compliance to Nasdaq (the “Plan”) and on November 26, 2024, the Company received notice from Nasdaq that it had accepted the Plan. In accordance with the Plan, the Company is required to complete a”
Christopher Cooper was appointed as interim co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..
“On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).”
Shuttle Pharmaceuticals Holdings, Inc. incurred revolving credit of up to $2,000,000 with certain lender identified on the signature page thereto at 18% per annum maturing first anniversary of the Closing Date.
“On February 28, 2025, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) entered into a Revolving Loan Agreement (the “Revolving Loan Agreement”) with certain lender identified on the signature page thereto (the “Lender”). Pursuant to and under the terms of the Revolving Loan Agreement, the Company issued to the Lender a revolving note dated February 28, 2025 in the principal amount of up to $2,000,000”
Oleh Nabyt was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..
“the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company”
Joseph Tung was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..
“the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company”
George Scorsis was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..
“the Company’s Board of Directors appointed George Scorsis, Joseph Tung, and Oleh Nabyt as directors of the Company”
Joshua Shafer resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..
“each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company”
Chris Senanayake resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..
“each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company”
Bette Jacobs resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..
“each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company”
Milton Brown resigned as Director at Shuttle Pharmaceuticals Holdings, Inc..
“each of Milton Brown, Bette Jacobs, Chris Senanayake and Joshua Shafer resigned as directors of the Company”
Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 30, 2024 the Company’s common stock had failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days, or until June 30, 2025 (the “Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum o”
Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“December 30, 2024 the Company’s common stock had failed to maintain a minimum closing bid price of $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2”
Michael Vander Hoek changed role as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..
“The Company’s current Chief Financial Officer, Mr. Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and, effective September 10, 2024, will assume the Vice President, Regulatory position on a full-time basis.”
Timothy J. Lorber was appointed as Chief Financial Officer at Shuttle Pharmaceuticals Holdings, Inc..
“On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.”
Shuttle Pharmaceuticals Holdings, Inc. reported preliminary financial results for first quarter ended March 31, 2024.
“On May 14, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), issued a press release providing a corporate update in connection with the filing of our Quarterly Report on Form 10-Q for the period ended March 31, 2024.”
Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“February 29, 2024, the Company received formal approval from Nasdaq granting it an additional 180 days, or until August 26, 2024 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If at any time before the Compliance Date the closing bid price for the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide the Company written confirmation that it has regained compliance with the Bid Price Requirement. If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Staff will p”
Shuttle Pharmaceuticals Holdings, Inc. entered into Purchase Agreement with SRO, LLC valued at $2,250,000 (effective 2024-02-07).
“Effective February 7, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“SHPH” or the “Company”), and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., a Maryland corporation (“Diagnostics”), entered into a securities purchase agreement (the “Purchase Agreement”) with SRO, LLC, a Nevada limited liability company (“SRO LLC”), pursuant to which SRO LLC agreed to commit to purchasing from the Company $2,250,000 of units (the “Units”) from the Company”
Shuttle Pharmaceuticals Holdings, Inc. entered into Asset Purchase Agreement with Alan Kozikowski and Werner Tueckmantel valued at Payment of $10,000 each upon signing; additional payments of $10,000 each upon receipt of a research (effective 2024-01-30).
“On January 30, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) and an Assignment of Invention Agreement (the “Assignment”) with Alan Kozikowksi and Werner Tueckmantel (together, the “Inventors”) pursuant to which the Inventors assigned all of their rights, title and interest in the invention entitled “PSMA-Boron” (the “Invention”) to the Company.”
Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Approval of the Company's Executive Compensation at the 2023-12-18 meeting.
“Shareholders approved (on an advisory basis) the Company’s executive compensation, in accordance with the voting results below.”
Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Ratification of the Company’s Independent Auditors at the 2023-12-18 meeting.
“Shareholders ratified the appointment of FORVIS LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023, in accordance with the voting results below.”
Shuttle Pharmaceuticals Holdings, Inc. shareholders approved Election of Directors at the 2023-12-18 meeting.
“All of the following six nominees were elected to the Company’s board of directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.”
Shuttle Pharmaceuticals Holdings, Inc. reported financial results for the quarter ended September 30, 2023.
“issued a press release providing a corporate update in connection with the filing of our quarterly report on Form 10-Q for the period ended September 30, 2023.”
Shuttle Pharmaceuticals Holdings, Inc. entered into License Agreement with Georgetown University (effective 2023-10-24).
“On October 24, 2023, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an exclusive licensing agreement (the “License Agreement”) with Georgetown University (“Georgetown”) pursuant to which Georgetown agreed to license the intellectual property known as “Predictive Biomarkers for Adverse Effects of Radiation Therapy” (U.S. Patent Application No. 17/476,184, filed on September 15, 2021) (the “Patent Rights”)”
Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“f $1.00 per share, as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days,”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.